What Is the Life Expectancy of Someone With Polycythemia?

Most people with polycythemia live with it for many years, and for the most common form, polycythemia vera, that often means decades rather than a few years. On average, though, lifespan is still somewhat shorter than for people without the disease.¹ The word “polycythemia” also covers two different situations: a slow blood cancer, or thick blood caused by another problem such as low oxygen. The outlook depends on which one you have.² Much of what shortens life in the cancer form is preventable, because the biggest early danger is blood clots, and treatment targets those directly.

How Long People With Polycythemia Vera Typically Live

Polycythemia vera (PV) is a slow blood cancer in which the bone marrow makes too many red cells, and often too many white cells and platelets. Age at diagnosis shapes the survival numbers more than anything else. People diagnosed at 40 or younger had a median survival of about 37 years. For those diagnosed at 41 to 60 it was about 22 years, and for those diagnosed over 60 it was about 10 years.³ A median is the point where half the group lives longer, so many people outlive these figures.

The 10-year figure for older patients does not mean PV kills most people within a decade. Someone diagnosed after 60 already has a shorter remaining lifespan from age alone, so comparing with other people the same age is the fairer way to read it.

Against that comparison, PV does shorten life. In a large group followed until most had died, median survival was 14.1 years, which was clearly worse than for people of the same age and sex without PV.⁴ The shortfall showed up in both younger and older patients.⁵ Some experts argue that a normal life expectancy is possible with modern care.⁶ Older figures may understate today’s outlook, because many patients in them were treated decades ago.

The numbers are also counted from diagnosis, and many people have the disease unnoticed for some time before it is found, so the clock does not start at the same point for everyone. Someone who is stable several years after diagnosis has already passed the early risks, and their remaining outlook is usually better than the original figure implied. A median describes a group and cannot predict one person’s course, so ask your hematologist which risk group you are in.

What Makes Your Outlook Better or Worse

Doctors can score risk using four things: age over 67, a white cell count of 15 or more (×10⁹/L), a past blood clot, and certain extra gene changes found in bone-marrow testing.⁷ Median survival was about 24 years in the low-risk group, 13 years in the intermediate group and about 3 years in the high-risk group.⁸ This score is fairly new and still needs confirming in more patients.⁹ A high-risk result is also uncommon, because it requires several factors at once, usually an adverse mutation plus older age.

Age and a past clot are the long-established markers that already decide how intensively many doctors treat, while white count and extra mutations add detail on top. Because the newer score relies on bone-marrow gene testing, people who never had that testing cannot be placed on it accurately.

Almost everyone with PV carries a change in a gene called JAK2, and tests can report what share of blood cells carry it. When more than half of the cells carried it, the risk of marrow scarring was higher.¹⁰ In one modelling estimate, people with a load below 50% lived about two years longer on average.¹¹ The mutation load did not predict leukemia or clots, though.¹²

Age and mutations are fixed, but clot risk and blood counts respond to treatment. A high white count may be brought down by medicines that slow the marrow.

What Shortens Life in Polycythemia Vera

Blood clots are the leading threat. About a third of deaths with a known cause in people with PV were from clots, such as strokes and heart attacks.¹³ Between 30% and 50% of people with PV have some clotting problem at some point.¹⁴ After a clot, the risk of death rose sharply, and people who had one within a year of diagnosis had a median survival of about 5 years.¹⁵ Heart disease accounted for the largest share of extra deaths not caused by cancer.¹⁶

Thick blood with too many cells slows flow and makes platelets and vessel walls more likely to form clots. Clots can form in arteries, causing strokes and heart attacks, or in veins, causing leg or abdominal clots, and both kinds occur in PV. Risk is greatest in people with a past clot or older age, which is why these groups are treated more intensively.

Sudden weakness, a drooping face or slurred speech can signal a stroke and need emergency care. Chest pain or breathlessness may mean a heart attack or a lung clot, and a swollen, painful calf may be a leg clot. Call emergency services immediately rather than waiting to reach your hematologist.

Over many years, PV can also turn into myelofibrosis, in which scar tissue fills the marrow, or into acute leukemia.¹⁷ In young patients, neither happened before about year 9, and by 20 years about 15% had leukemia and 10% marrow scarring.¹⁸ After PV turns into marrow scarring, median survival was about 5.7 years, and shorter if hemoglobin is below 10 g/dL.¹⁹ Leukemia was about 13 times more common as a cause of death than in the general population.²⁰

Growing fatigue, night sweats or weight loss can suggest progression. An enlarging spleen may cause early fullness or discomfort on the left side. Needing fewer blood removals, or falling counts, can paradoxically signal scarring. Report these changes rather than waiting for the next routine visit.

Bleeding is a smaller risk. Major bleeding is more common than in people without PV,²¹ and it caused up to about 14% of deaths, mostly bleeding in the brain.²²

How Treatment Protects Your Lifespan

Your blood test reports hematocrit, the share of your blood made up of red cells. Over about two and a half years, clots or heart deaths happened in about 3% of people kept below 45%, versus about 10% of those kept at 45–50%.²³ Below 45% is the standard target, usually reached by removing blood much like a donation.²⁴ In the months before death, more than a quarter of patients had a high hematocrit or uncontrolled counts.²⁵ So keep to your blood-removal and lab schedule even when you feel fine.

A result at or above 45% usually prompts more blood removal or a change in medicine. A single result can be affected by dehydration, so your doctor looks at the pattern across visits. Feeling well is not a reliable guide, because thick blood often causes no symptoms until a clot happens.

Early on, blood may be removed weekly until the target is reached. After that, sessions are spaced out to keep hematocrit steady. Drinking fluids before a session can ease dizziness. Most people also take low-dose aspirin unless told otherwise.

Medicines that slow the marrow add another layer. Longer time on interferon was linked to lower rates of marrow scarring and lower death rates, while hydroxyurea showed no such link.²⁶ With ropeginterferon, progression was about 0.2% per year versus about 1% on standard treatment.²⁷ Ruxolitinib improved control but showed similar 5-year survival, about 92% versus 91%.²⁸

Hydroxyurea is a long-used tablet that controls counts. Interferon is injected and is often preferred in younger people. Ruxolitinib is used when hydroxyurea fails or isn’t tolerated. The best choice depends on age, clot history and side effects.

Heart risk factors add up too. PV raises heart risk on its own, and high blood pressure, smoking and high cholesterol add to it.²⁹ Stopping smoking and treating blood pressure and cholesterol are among the most useful things you can do.

Life Expectancy When You’re Diagnosed Young

Younger patients were more likely to have low-risk disease and fewer artery clots, but they had more vein clots, such as in the abdomen or legs.³⁰ Marrow scarring developed in 22% over about 11 years, partly because they lived long enough for it to happen.³¹ In another group of young patients, 62% were alive at 20 years.³² Even a small yearly risk of progression adds up over several decades, so long-term follow-up matters.

That makes treatments that protect the marrow over decades more important, and asking about interferon is reasonable at this age. Regular checks of the spleen and counts help catch change early, and life and work planning can assume many years ahead.

Clots in abdominal veins can cause belly pain or swelling, and they are a known way PV first shows up in young people. Report unexplained abdominal pain promptly.

Outlook for Secondary and Inherited Polycythemia

In secondary polycythemia, the outlook mostly depends on what is causing it.³³ In lung disease such as COPD, severe low oxygen raises red cells, and oxygen therapy lowers the risk.³⁴ Clot and death risks seem tied to the underlying illness more than to the high red count itself.³⁵ Treating the cause, such as low oxygen, smoking or sleep apnea, is the priority.

The bone marrow here is responding normally to a signal, usually low oxygen, so the high red count is a symptom rather than the disease. Removing blood is not usually the main treatment, because the cause keeps driving red cells up and the count tends to climb again. Some people do need careful management of very high counts, which is a decision for the doctor treating the underlying condition.

A JAK2 test is usually positive in PV and negative in secondary forms, though doctors combine it with other results rather than relying on it alone. Hormone levels that drive red cell production tend to be low in PV and normal or high otherwise. Smoking, testosterone use and sleep apnea are common secondary causes, so ask which type you have before reading survival figures.

Rare inherited forms can shorten life. In one of them, 29% of patients reached 65 compared with 64% of neighbors.³⁶ Strokes and clots drove much of that early death.³⁷

Pregnancy, Daily Life and Access to Care

In one series, about half of pregnancies in women with PV ended in a live birth.³⁸ With PV-specific treatment, live births rose to 69% versus 8% without it.³⁹ Aspirin and interferon are generally considered suitable in pregnancy,⁴⁰ so plan pregnancy with your hematologist.

The main risks are clots and loss of the pregnancy, which is why these pregnancies are managed as high risk. Some PV drugs, such as hydroxyurea, are not suitable in pregnancy, so a change of medicine may be needed before conceiving. Blood counts are checked more often during pregnancy and after delivery, when clot risk remains raised.

Many people with PV carry a heavy symptom load, such as fatigue and itching, that limits daily life.⁴¹ Fatigue is worth reporting, not just enduring. Itching after warm showers is typical and can be treated. Tracking symptoms helps your doctor adjust treatment.

Access to care matters as well. People in underserved areas were diagnosed about 2.6 years later,⁴² and better insurance coverage in a community was linked to better survival.⁴³ Missed follow-ups let counts drift up unnoticed. If costs threaten treatment, ask about patient assistance, and remember that a hematologist experienced in PV and related marrow disorders can be consulted even remotely.